期刊文献+

Role of selected criteria and preventive chemotherapy in tumor recurrence after liver transplantation 被引量:2

下载PDF
导出
摘要 Background:Long-term survival after liver transplantation(LT)for hepatocellular carcinoma(HCC)patients remains poor because of tumor recurrence.To improve the prognosis of HCC patients after LT,we aimed to identify different transplantation criteria and risk factors related to tumor recurrence and evaluate the effect of preventive chemotherapy in a single center.Methods:In total,data on 20 variables and the survival of 199 patients with primary HCC who underwent LT between 2005 and 2015 were included for analysis.The patients were divided into the following three groups:Group 1,within the Milan and Hangzhou criteria(n=51);Group 2,beyond the Milan but within the Hangzhou criteria(n=36);and Group 3,beyond the Milan and Hangzhou criteria(n=112).Survival probabilities for the three groups were calculated using multivariate Cox regression analysis.The association between preventive therapy and HCC-recurrence after LT was analyzed by multiple logistic regression analysis.Results:Child-Pugh stage C and hepatitis B virus(HBV)infection were independent risk factors for patients with tumor recurrence who did not meet the Milan criteria.The overall survival rates of the 199 patients showed statistically significant differences among the three groups(P<0.001).Moreover,no significant difference was noted in the survival rate between Group 1 and Group 2(P>0.05).Multivariate logistic regression analysis showed that postoperative prophylactic chemotherapy reduced the risk of tumor recurrence in patients who did not meet the Hangzhou and Milan criteria(OR=0.478;95%CI:0.308–0.741;P=0.001).Conclusions:Child-Pugh classification and HBV infection were the independent risk factors of tumor recurrence in HCC patients with LT.The Hangzhou criteria were effective and analogous compared with the Milan criteria.Preventive chemotherapy significantly reduced the risk of recurrence and prolonged the survival time for HCC patients beyond the Milan and Hangzhou criteria after LT.
出处 《Hepatobiliary & Pancreatic Diseases International》 SCIE CAS CSCD 2020年第4期378-383,共6页 国际肝胆胰疾病杂志(英文版)
基金 grants from the National Natural Science Foundation of China(No.81770652) Science and Technology Foundation of Hubei Province(No.2017ACA096 and WJ2017Z011).
  • 相关文献

参考文献2

二级参考文献184

  • 1Bo Zhai,Xue-Ying Sun.Mechanisms of resistance to sorafenib and the corresponding strategies in hepatocellular carcinoma[J].World Journal of Hepatology,2013,5(7):345-352. 被引量:26
  • 2Roberto Mazzanti,Luca Messerini,Camilla E Comin,Lorenzo Fedeli,Nathalie Gannè-Carrie,Michel Beaugrand.Liver angiogenesis as a risk factor for hepatocellularcarcinoma development in hepatitis C virus cirrhotic patients[J].World Journal of Gastroenterology,2007,13(37):5009-5014. 被引量:3
  • 3El-Serag HB. Epidemiology of viral hepatitis and hepatocellularcarcinoma. Gastroenterology 2012; 142: 1264-1273.e1 [PMID:22537432 DOI: 10.1053/j.gastro.2011.12.061].
  • 4Rahman El-Zayadi A, Abaza H, Shawky S, Mohamed MK,Selim OE, Badran HM. Prevalence and epidemiological featuresof hepatocellular carcinoma in Egypt-a single center experience.Hepatol Res 2001; 19: 170-179 [PMID: 11164741 DOI: 10.1016/S1386-6346(00)00105-4].
  • 5el-Zayadi AR, Badran HM, Barakat EM, Attia Mel-D, ShawkyS, Mohamed MK, Selim O, Saeid A. Hepatocellular carcinoma inEgypt: a single center study over a decade. World J Gastroenterol2005; 11: 5193-5198 [PMID: 16127751].
  • 6el-Serag HB. Epidemiology of hepatocellular carcinoma. ClinLiver Dis 2001; 5: 87-107, vi [PMID: 11218921 DOI: 10.1016/S1089-3261(05)70155-0].
  • 7Arafa N, El Hoseiny M, Rekacewicz C, Bakr I, El-Kafrawy S,El Daly M, Aoun S, Marzouk D, Mohamed MK, Fontanet A.Changing pattern of hepatitis C virus spread in rural areas of Egypt.J Hepatol 2005; 43: 418-424 [PMID: 16019104 DOI: 10.1016/j.jhep.2005.03.021].
  • 8Strickland GT, Elhefni H, Salman T, Waked I, Abdel-HamidM, Mikhail NN, Esmat G, Fix A. Role of hepatitis C infectionin chronic liver disease in Egypt. Am J Trop Med Hyg 2002; 67:436-442 [PMID: 12452500].
  • 9Moradpour D, Blum HE. Pathogenesis of hepatocellularcarcinoma. Eur J Gastroenterol Hepatol 2005; 17: 477-483 [PMID:15827436 DOI: 10.1097/00042737-200505000-00002].
  • 10Singal A, Volk ML, Waljee A, Salgia R, Higgins P, Rogers MA,Marrero JA. Meta-analysis: surveillance with ultrasound for earlystagehepatocellular carcinoma in patients with cirrhosis. AlimentPharmacol Ther 2009; 30: 37-47 [PMID: 19392863 DOI: 10.1111/j.1365-2036.2009.04014.x].

共引文献59

同被引文献19

引证文献2

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部